| Microglial phagocytosis and its regulation: a therapeutic target in Parkinson’s disease? E Janda, L Boi, AR Carta Frontiers in molecular neuroscience 11, 144, 2018 | 196 | 2018 |
| Boosting phagocytosis and anti‐inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson's disease models D Lecca, E Janda, G Mulas, A Diana, C Martino, F Angius, S Spolitu, ... British journal of pharmacology 175 (16), 3298-3314, 2018 | 53 | 2018 |
| Immunomodulatory drugs alleviate l‐dopa‐induced dyskinesia in a rat model of Parkinson's disease L Boi, A Pisanu, NH Greig, MT Scerba, D Tweedie, G Mulas, S Fenu, ... Movement Disorders 34 (12), 1818-1830, 2019 | 49 | 2019 |
| Neuroinflammation in l-DOPA-induced dyskinesia: beyond the immune function A Pisanu, L Boi, G Mulas, S Spiga, S Fenu, AR Carta Journal of Neural Transmission 125, 1287-1297, 2018 | 43 | 2018 |
| Trimethyl chitosan hydrogel nanoparticles for progesterone delivery in neurodegenerative disorders MC Cardia, AR Carta, P Caboni, AM Maccioni, S Erbì, L Boi, MC Meloni, ... Pharmaceutics 11 (12), 657, 2019 | 37 | 2019 |
| Modeling Parkinson’s disease neuropathology and symptoms by intranigral inoculation of preformed human α-synuclein oligomers L Boi, A Pisanu, MF Palmas, G Fusco, E Carboni, MA Casu, V Satta, ... International Journal of Molecular Sciences 21 (22), 8535, 2020 | 27 | 2020 |
| Advances in modelling alpha-synuclein-induced Parkinson’s diseases in rodents: virus-based models versus inoculation of exogenous preformed toxic species AR Carta, L Boi, A Pisanu, MF Palmas, E Carboni, A De Simone Journal of Neuroscience Methods 338, 108685, 2020 | 26 | 2020 |
| A hypothalamic dopamine locus for psychostimulant-induced hyperlocomotion in mice S Korchynska, P Rebernik, M Pende, L Boi, A Alpár, R Tasan, K Becker, ... Nature Communications 13 (1), 5944, 2022 | 24 | 2022 |
| Treatment with gut bifidobacteria improves hippocampal plasticity and cognitive behavior in adult healthy rats G Talani, F Biggio, MC Mostallino, V Locci, C Porcedda, L Boi, E Saolini, ... Neuropharmacology 165, 107909, 2020 | 20 | 2020 |
| Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s Disease MA Casu, I Mocci, R Isola, A Pisanu, L Boi, G Mulas, NH Greig, MD Setzu, ... Frontiers in Aging Neuroscience 12, 31, 2020 | 19 | 2020 |
| A mouse model of sleep disorders in Parkinson’s disease showing distinct effects of dopamine D2-like receptor activation D de Castro Medeiros, C Plewnia, RV Mendes, CA Pisanò, L Boi, ... Progress in Neurobiology 231, 102536, 2023 | 4 | 2023 |
| Metabolomics fingerprint induced by the intranigral inoculation of exogenous human alpha-synuclein oligomers in a rat model of Parkinson’s disease F Murgia, L Atzori, E Carboni, ML Santoru, A Hendren, A Pisanu, ... International Journal of Molecular Sciences 21 (18), 6745, 2020 | 4 | 2020 |
| Serotonergic and dopaminergic neurons in the dorsal raphe are differentially altered in a mouse model for parkinsonism L Boi, Y Johansson, R Tonini, R Moratalla, G Fisone, G Silberberg ELife 12, RP90278, 2024 | 3 | 2024 |
| Investigating affective neuropsychiatric symptoms in rodent models of Parkinson’s disease L Boi, G Fisone International Review of Neurobiology 174, 119-186, 2024 | 1 | 2024 |
| Serotonergic and dopaminergic neurons in the dorsal raphe are differentially altered in a mouse model for Parkinson’s disease L Boi, Y Johansson, R Tonini, R Moratalla, G Fisone, G Silberberg bioRxiv, 2023.07. 21.550014, 2023 | 1 | 2023 |
| Dopamine D2 receptor activation counteracts olfactory dysfunction and related cellular abnormalities in experimental parkinsonism D Medeiros, D Masini, C Plewnia, L Boi, M Rosati, N Scalbert, G Fisone Heliyon 10 (16), 2024 | | 2024 |
